Vancouver, B.C. and Boston, MA, January 30, 2018 – Imagin Medical Inc. (CSE: IME) (OTC PINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the “Company”) announced today the offering of a non-brokered private placement to raise $200,000 through the issuance of 625,000 shares at a price of $0.32 per share.
The funds raised pursuant to the financing will be specifically allocated for the Company’s ongoing communications and marketing program, allowing the Company to continue to maintain its existing cash for product development and commercialization.
The Company expects to close the private placement immediately after submitting the required filings with the regulatory authorities.
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer where endoscopes are used. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imagindev.wpengine.com.
For further information, contact:
Jim Hutchens, President & CEO
Email: [email protected]
Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected, except as required under applicable securities legislation; the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release. U.S. HQ: 69 Longwood Avenue CA HQ: 890 West Pender Street, Suite 600 Hyannis Port, MA 02647 Vancouver, British Columbia USA Canada V6C 1J9 617-571-6006 778-998-5000; 604-687-1327 (fax)